Results 81 to 90 of about 4,368 (201)

Finerenone: Will It Be a Game-changer?

Cardiac Failure Review
Heart failure (HF) is a major contributor to hospitalisations and accounts for 7% of cardiovascular-related deaths, with patients who have chronic kidney disease and type 2 diabetes at heightened risk. Existing treatment guidelines inadequately address these comorbidities.
Dinesh Khullar, Anish Kumar Gupta, Kulwant Singh   +2 more
openaire   +2 more sources

Cardioprotective Effects of Finerenone Associated With the Suppression of Myocardial Sodium Accumulation in Aldosterone/Salt‐Loaded Rats

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Clinical trials have indicated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, elicits considerable cardiovascular protective benefits; however, its precise mechanism of action remains to be fully elucidated.
Asadur Rahman, Tatsuya Sawano, Kento Kitada, Nourin Jahan, Yoshihide Fujisawa, Keiko Yamakawa, Md Moshiur Rahman, Juanjuan Ye, Md Enayet Kabir, Kyuichi Kadota, Takeshi Imamura, Hiroyuki Ohsaki, Daisuke Yamazaki, Takashi Morikawa, Yoshio Konishi, Akira Nishiyama   +15 more
doaj   +1 more source

PROCESS FOR THE PREPARATION OF FINERENONE [PDF]

The present invention relates to a process for the preparation of Finerenone, a compound of formula I, and intermediates ...
Venukathala, Prashanth, Mr., Venukathala, Prashanth   +1 more
core  

Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY

Background: Anemia is common in patients with chronic kidney disease and type 2 diabetes. Finerenone improved heart and kidney outcomes in patients with chronic kidney disease and type 2 diabetes in FIDELITY.
James, Glen, Singh, Ajay K., Roberts, Luke, Rossing, Peter, Pitt, Bertram, Farjat, Alfredo E., Filippatos, Gerasimos, Anker, Stefan D., Ruilope, Luis M., Farag, Youssef M.K.   +9 more
core   +2 more sources

In Reply to ‘Finerenone: Fiddling With Hyperkalemia?’ [PDF]

American Journal of Kidney Diseases, 2021
Vikas S, Sridhar, Hongyan, Liu, David Z I, Cherney   +2 more
openaire   +2 more sources

Finerenone in People with Chronic Kidney Disease, Type 2 Diabetes, and History of Nephrectomy

Finerenone significantly reduced the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis of two phase 3 trials.
Horvat-Broecker, Andrea, Brinker, Meike, Anker, Stefan D, Rohwedder, Katja, FIDELIO-DKD and FIGARO-DKD Investigators, Filippatos, Gerasimos, Rossing, Peter, Weir, Matthew R, Ahlers, Christiane, Fatoba, Samuel T, Mendoza, Jair Munoz, Fornoni, Alessia, Fatoba, Samuel T., Anker, Stefan D., Weir, Matthew R.   +14 more
core   +1 more source

Finerenone mitigates acute alcoholic myocardial injury by modulating inflammatory signaling, oxidative stress, and mitochondrial function

Molecular Medicine
Background and purpose Alcoholic cardiomyopathy (ACM) is a serious complication of chronic and acute alcohol abuse that can progress to heart failure (HF).
Ching-Han Liu, Tian-Huei Chu, Shih-Ming Yang, Yi-Chen Wang, Wen-Chin Lee, Yi-Chen Chang, Yao-Chang Chen, Yi-Jen Chen, Cheng-Chieh Fang, Zhi-Hong Wen, Chien-Wei Feng, Hao-Ming Wu, Po-Tseng Lee, Nan-Chieh Huang, Shih-Chung Huang   +14 more
doaj   +1 more source

Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials. [PDF]

BACKGROUND: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a novel therapeutic option for the management of patients with diabetes, chronic kidney disease, or heart failure. We seek to summarize the evidence on the drugs
Maniya, Muhammad, Fonarow, Gregg, Shafiq, Aimen, Ahmed, Mushood, Iqbal, Javed, Fudim, Marat, Rana, Jamal, Jain, Hritvik, Naveed, Muhammad, Ahmed, Raheel, Ahsan, Areeba   +10 more
core   +1 more source

Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States

Journal of Clinical & Translational Endocrinology
Background: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improves renal and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Csaba P. Kovesdy, Craig I. Coleman, Catherine B. Johannes, Anam M. Khan, Ryan Ziemiecki, J. Bradley Layton, David Vizcaya, Fangfang Liu, Nikolaus G. Oberprieler   +8 more
doaj   +1 more source

Finerenone attenuates chronic fibrotic remodeling during the AKI-CKD transition in an ischemia-reperfusion-induced acute kidney injury mouse model

Renal Failure
Objective: The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) is a major cause of poor prognosis in renal injury, and preventing the progression from AKI to CKD has important clinical significance.
Ruoshan Lian, Siyi Rao, Zongli Zheng, Sha Tang, Jianxin Wan, Yi Chen   +5 more
doaj   +1 more source